BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Figure 3. Actuarial prostate-specific antigen (PSA) relapse-free survival according to pre-treatment PSA. PSA-RFS is 81.4%, 69.8%, and 36.3% for patients cohorts of PSA less or equal to 10, 10.1–20, and greater than 20, respectively (p<0.0001) (solid line, PSA≤10; dashed PSA 10.1–20; dotted PSA>20). Initial PSA is a predictive tool of PSA control.





Right arrow Return to article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS